VIR · Vir Biotechnology, Inc.
$8.64
-0.21 (-2.37%)
At close · Jul 29
Market Cap
$1.46B
Shares
168.65M
Vir Biotechnology, Inc. Earnings Call Transcripts
Every quarterly earnings call for Vir Biotechnology, Inc. (VIR) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
·
$3.80M
−$194.78M
'23 Q2
23-08-03
▼99.3%
$2.64M
−$163.41M
'23 Q3
23-11-02
▼66%
$16.79M
−$115.92M
'23 Q4
24-02-22
▼10.5%
$56.38M
−$65.28M
'24 Q1
24-05-02
▼19%
$3.08M
−$138.38M
'24 Q2
24-08-01
▼9.8%
$2.38M
−$213.72M
'24 Q3
24-10-31
▼26.3%
$12.37M
−$104.59M
'24 Q4
25-02-26
▼94.6%
$3.03M
−$120.97M
'25 Q1
25-05-27
▼60.5%
$1.21M
−$110.96M
'25 Q2
25-08-06
▼89.9%
$240,000
−$163.14M
'25 Q3
25-11-05
▲417.8%
$64.07M
−$42.92M
'25 Q4
26-02-23
LATEST
▼101%
$
−$125.69M
'26 Q1
26-05-06
Earnings call
FY26 · Q2
2026-08-05
Vir Biotechnology Second Quarter 2026 Corporate Update and Financial Results Conference Call
Scheduled
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-06
Vir Biotechnology, Inc. Q1 FY2026 Earnings Call
Confident tone
Astellas collaboration / VIR-5500 prostate cancer
Hepatitis delta (tobevibart + elebsiran) and ECLIPSE trials
Other T cell engager pipeline (VIR-5818, VIR-5525)
Revenue
$
▼ 101% YoY Diluted EPS
$-0.85
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-10
Leerink Partners Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-03-02
TD Cowen 46th Annual Health Care Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-23
Vir Biotechnology, Inc. Q4 FY2025 Earnings Call
Confident tone
Strategic collaboration with Astellas
Dose escalation and therapeutic index optimization
Pro-X10 platform validation
Revenue
$64.07M*
▲ 417.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Conference
Investor event
2026-01-14
44th Annual J.P. Morgan Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q3
2025-11-05
Vir Biotechnology, Inc. Q3 FY2025 Earnings Call
Confident tone
Eclipse Phase 3 Hepatitis Delta Program
VIR-5500 PSMA T-cell Engager
Solstice Phase 2 Data and ASLD Presentation
Revenue
$240,000
▼ 89.9% YoY Diluted EPS
$-1.17
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Vir Biotechnology, Inc. Q2 FY2025 Earnings Call
Confident tone
T Cell Engager Oncology Portfolio (PRO-XTEN)
Hepatitis Delta / ECLIPSE Program
PSMA / VIR-5500 Prostate Cancer
Revenue
$1.21M
▼ 60.5% YoY Diluted EPS
$-0.80
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-27
Vir Biotechnology, Inc. Q1 FY2025 Earnings Call
Revenue
$3.03M
▼ 94.6% YoY Diluted EPS
$-0.88
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-26
Vir Biotechnology, Inc. Q4 FY2024 Earnings Call
Confident tone
T-cell engager oncology platform and PRO-XTEN
Hepatitis B functional cure and partnership strategy
Hepatitis delta (HDV) program and ECLIPSE Phase III
Revenue
$12.37M*
▼ 26.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Vir Biotechnology, Inc. Q3 FY2024 Earnings Call
Confident tone
Sanofi licensing deal and T-cell engagers
Hepatitis B (HBV) functional cure program
Upcoming investor events and AASLD data
Revenue
$2.38M
▼ 9.8% YoY Diluted EPS
$-1.56
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Vir Biotechnology, Inc. Q2 FY2024 Earnings Call
Confident tone
Sanofi license agreement / masked T-cell engagers
Cancer therapeutics landscape and unmet need
Revised 2024 expense guidance
Revenue
$3.08M
▼ 19% YoY Diluted EPS
$-1.02
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Vir Biotechnology, Inc. Q1 FY2024 Earnings Call
Positive tone
Hepatitis delta / SOLSTICE trial
Hepatitis B functional cure / MARCH trial
Regulatory engagement and Phase III planning
Revenue
$56.38M
▼ 10.5% YoY Diluted EPS
$-0.48
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
Vir Biotechnology, Inc. Q4 FY2023 Earnings Call
Confident tone
Financial position and capital allocation
Leadership transition (CMO departure)
Influenza antibodies / GSK collaboration termination
Revenue
$16.79M*
▼ 66% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Vir Biotechnology, Inc. Q3 FY2023 Earnings Call
Revenue
$2.64M
▼ 99.3% YoY Diluted EPS
$-1.22
▼ 193.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Vir Biotechnology, Inc. Q2 FY2023 Earnings Call
Revenue
$3.80M
Diluted EPS
$-1.45
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–16 of 16 earnings calls
Key facts
CIK
1706431
CUSIP
92764N102
13F (30d)
44 filings
44 filers
Visit website
Investor relations